<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05121831</url>
  </required_header>
  <id_info>
    <org_study_id>DGX-001-01</org_study_id>
    <nct_id>NCT05121831</nct_id>
  </id_info>
  <brief_title>A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of DGX-001</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of DGX-001 in Healthy Volunteers Followed by a Stress Exposure Resilience Panel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Digestome Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Digestome Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, randomized, double-blind, placebo-controlled, SAD and MAD study in healthy&#xD;
      adult volunteers. DGX-001 is a peptide being investigated for the treatment of the major&#xD;
      depressive disorder. This study will examine the safety and tolerability of increasing doses&#xD;
      of DGX-001 and, in an exploratory way, potential moderators and functional markers of its&#xD;
      activity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in three parts, Part 1 consisting of SAD cohorts and Part 2&#xD;
      consisting of MAD cohorts and Part 3 consisting of two cohorts of stress exposure resilience&#xD;
      panel. In Part 1, approximately 32 adult healthy volunteers will be enrolled sequentially&#xD;
      into 1 of 4 single-dose cohorts and will be randomized to receive either a dose of DGX-001 or&#xD;
      a placebo. In Part 2, approximately 24 adult healthy volunteers will be enrolled into 1 of 3&#xD;
      multiple-dose cohorts. An adaptive dose-escalation schedule will be employed for both the SAD&#xD;
      and MAD parts of the study. In Part 3, 28 subjects will be enrolled into 1 of 2 cohorts to&#xD;
      further explore the pharmacodynamic effect of DGX-001 under a physiological challenge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 11, 2022</start_date>
  <completion_date type="Anticipated">November 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 22, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part 1 and Part 2 of the study will have a parallel assignment and Part 3 of the study will have a parallel assignment with a crossover design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Day1- Day14</time_frame>
    <description>A TEAE is any event that is not present before the initiation of the investigational product or any event already present that worsens in either intensity or frequency following exposure to the investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of treatment-emergent adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>Day 1- Day14</time_frame>
    <description>A TEAE is any event that is not present before the initiation of the investigational product or any event already present that worsens in either intensity or frequency following exposure to the investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal and clinically significant safety laboratory tests</measure>
    <time_frame>Day 1- Day 14</time_frame>
    <description>Safety laboratory tests include clinical chemistry and hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal and clinically significant electrocardiogram test</measure>
    <time_frame>Day 1- Day 21</time_frame>
    <description>12 lead ECGs will be collected in triplicate, which will measure heart rate, PR, QRS, QT, QTc</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal and clinically significant urinalysis findings</measure>
    <time_frame>Day 1-Day 21</time_frame>
    <description>This will include routine urine test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCt in SAD and MAD</measure>
    <time_frame>Day 1-Day 9</time_frame>
    <description>Total exposure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC24 in SAD and MAD</measure>
    <time_frame>Day 1-Day 9</time_frame>
    <description>Area under plasma concentration -time curve at 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC∞ in SAD and MAD</measure>
    <time_frame>Day 1-Day 9</time_frame>
    <description>Area under plasma concentration -time from time 0 to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax in SAD and MAD</measure>
    <time_frame>Day 1-day 9</time_frame>
    <description>Maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax in SAD and MAD</measure>
    <time_frame>Day 1-Day 9</time_frame>
    <description>Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 in SAD and MAD</measure>
    <time_frame>Day 1-Day 9</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F in SAD and MAD</measure>
    <time_frame>Day 1-Day 9</time_frame>
    <description>Oral clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F in SAD and MAD</measure>
    <time_frame>Day 1-Day 9</time_frame>
    <description>Apparent volume of distribution during terminal phase after non-intravenous administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz in SAD and MAD</measure>
    <time_frame>Day 1-Day 9</time_frame>
    <description>Elimination rate constant</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose Cohort S1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of either dose level 1 of DGX-001 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose Cohort S2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of either dose level 2 of DGX-001 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose Cohort S3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of either dose level 3 of DGX-001 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose Cohort S4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of either dose level 4 of DGX-001 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Doses Cohort M1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive multiple doses of either dose level 1 of DGX-001 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Doses Cohort M2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive multiple doses of either dose level 2 of DGX-001 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Doses Cohort M3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive multiple doses of either dose level 3 of DGX-001 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stress Exposure Resilience Panel Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive any of the MAD dose panel or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stress Exposure Resilience Panel Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive any of the MAD dose panel or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DGX-001Dose 1</intervention_name>
    <description>Dose level 1 of DGX-001</description>
    <arm_group_label>Multiple Ascending Doses Cohort M1</arm_group_label>
    <arm_group_label>Single Ascending Dose Cohort S1</arm_group_label>
    <other_name>DGX-001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DGX-001 Dose 2</intervention_name>
    <description>Dose level 2 of DGX-001</description>
    <arm_group_label>Multiple Ascending Doses Cohort M2</arm_group_label>
    <arm_group_label>Single Ascending Dose Cohort S2</arm_group_label>
    <other_name>DGX-001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DGX-001 Dose 3</intervention_name>
    <description>Dose level 3 of DGX-001</description>
    <arm_group_label>Multiple Ascending Doses Cohort M3</arm_group_label>
    <arm_group_label>Single Ascending Dose Cohort S3</arm_group_label>
    <other_name>DGX-001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DGX-001 Dose 4</intervention_name>
    <description>Dose level 4 of DGX-001</description>
    <arm_group_label>Single Ascending Dose Cohort S4</arm_group_label>
    <other_name>DGX-001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAD dose panel of DGX-001</intervention_name>
    <description>Dose levels confirmed through SAD and MAD</description>
    <arm_group_label>Stress Exposure Resilience Panel Cohort 1</arm_group_label>
    <arm_group_label>Stress Exposure Resilience Panel Cohort 2</arm_group_label>
    <other_name>DGX-001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match</description>
    <arm_group_label>Multiple Ascending Doses Cohort M1</arm_group_label>
    <arm_group_label>Multiple Ascending Doses Cohort M2</arm_group_label>
    <arm_group_label>Multiple Ascending Doses Cohort M3</arm_group_label>
    <arm_group_label>Single Ascending Dose Cohort S1</arm_group_label>
    <arm_group_label>Single Ascending Dose Cohort S2</arm_group_label>
    <arm_group_label>Single Ascending Dose Cohort S3</arm_group_label>
    <arm_group_label>Single Ascending Dose Cohort S4</arm_group_label>
    <arm_group_label>Stress Exposure Resilience Panel Cohort 1</arm_group_label>
    <arm_group_label>Stress Exposure Resilience Panel Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female healthy adult volunteers between 18 to 65 years of age (Both&#xD;
             inclusive).&#xD;
&#xD;
          2. The subject's BMI is between 18 and 32 kg/m2.&#xD;
&#xD;
          3. Female subjects with childbearing potential must have a negative serum pregnancy test.&#xD;
&#xD;
          4. The subject is medically healthy with no clinically significant or relevant&#xD;
             abnormalities in medical history, physical exam, vital signs, electrocardiogram (ECG),&#xD;
             and laboratory evaluations (hematology, chemistry, and urinalysis) as assessed by the&#xD;
             Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject has a current or recurrent disease that could affect the action,&#xD;
             absorption or disposition of the investigational medicinal product or could affect&#xD;
             clinical or laboratory assessments.&#xD;
&#xD;
          2. The subject has abnormal renal function test ( &lt;60mL/min, i.e., GFR by Cockroft/Gault)&#xD;
             at screening or baseline.&#xD;
&#xD;
          3. The subject has evidence of Gilbert's Syndrome or abnormal liver function test (LFTs&#xD;
             &gt;1.5x ULN) at screening or baseline.&#xD;
&#xD;
          4. The subject has had a cholecystectomy or a history of cholecystitis.&#xD;
&#xD;
          5. The subject has clinically significant 12-lead ECG abnormalities, including QTc of&#xD;
             450ms for males and 470ms for females (average of triplicate measures) for any&#xD;
             pre-randomization ECG assessment.&#xD;
&#xD;
          6. The subject has a current or relevant history of physical or psychiatric illness.&#xD;
&#xD;
          7. The subject has a documented history of HIV antibody or tested positive for hepatitis&#xD;
             B surface antigen (HBsAg) or Hepatitis C virus (HCV) antibody at screening.&#xD;
&#xD;
          8. The subject received an investigational agent within the last 30 days prior to&#xD;
             Screening or five half-lives (if known) prior to Screening.&#xD;
&#xD;
          9. The subject has a history of alcohol or other substance abuse within the 12 months&#xD;
             prior to dosing.&#xD;
&#xD;
         10. The subject is currently using any medication (including over-the-counter [OTC],&#xD;
             herbal or homeopathic preparations), except for hormonal replacement therapy or&#xD;
             hormonal contraceptives, that in the opinion of the investigator can not be&#xD;
             discontinued and avoided for four weeks before the first dose throughout the study&#xD;
             period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor Grachev</last_name>
    <role>Study Director</role>
    <affiliation>Digestome Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Igor Grachev</last_name>
    <phone>1-732-642-7773</phone>
    <email>igor@digestometx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ken Horne</last_name>
    <phone>(650) 814-1639</phone>
    <email>ken@digestometx.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

